Dual Antiplatelet Therapy or Aspirin after Coronary Bypass Surgery
New England Journal of Medicine · 26.03.2026 · 394 (12) · 1243-1244
DOI: 10.1056/nejmc2600235 ↗Kurz gefasst
Leserbrief in der Zeitschrift New England Journal of Medicine, erschienen am 26.03.2026. Verfasst von Yujun He. Beteiligte Einrichtung: Taizhou Hospital of Zhejiang Province, Taizhou, China. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
To the Editor: In their article on the TACSI trial (Dec. 11 issue) 1 regarding the use of ticagrelor plus aspirin or aspirin alone after coronary-artery bypass grafting (CABG), Jeppsson and colleagues have overlooked two critical confounders that may have obscured the true biologic efficacy of ticagrelor. First, the effect of the concomitant use of oral anticoagulants was underappreciated. At 1 year, 12.8% of the patients in the group receiving dual antiplatelet therapy and 11.5% of those in the monotherapy group were also receiving oral anticoagulants. Thus, a subset of patients were effectively receiving high-risk triple therapy, which could have confounded . . .
Autor:innen und Institutionen
- Taizhou Hospital of Zhejiang Province, Taizhou, China.
Zitieren
APA
He, Y. (2026). Dual Antiplatelet Therapy or Aspirin after Coronary Bypass Surgery. New England Journal of Medicine, 394(12), 1243-1244. https://doi.org/10.1056/nejmc2600235
Vancouver
He Y. Dual Antiplatelet Therapy or Aspirin after Coronary Bypass Surgery. New England Journal of Medicine. 2026;394(12):1243-1244. doi:10.1056/nejmc2600235
BibTeX
@article{He2026,
author = {He, Yujun},
title = {Dual Antiplatelet Therapy or Aspirin after Coronary Bypass Surgery},
journal = {New England Journal of Medicine},
year = {2026},
volume = {394},
number = {12},
pages = {1243--1244},
doi = {10.1056/nejmc2600235}
}
EUVIMED